Pharmacist-Led Quality Improvement Project to Optimize Abemaciclib Dosing Within a Community Oncology Network

Dose interruption and/or dose reduction of the monarchE trial: 43.7% of patients treated with adjuvant Verzenio (abemaciclib) may be required based on individual Verzenio required dose reductions, most commonly for safety and tolerability in patients with breast cancer. In the diarrhea. Reductions were shown to effectively manage adverse events, with only 8.9% of patients discontinuing after a dose reduction; however, 52% of patients who discontinued Verzenio due to an adverse event did not have a prior dose reduction. Data have shown that the efficacy of adjuvant Verzenio is not compromised by dose reductions for patients with high-risk early-stage breast cancer or advanced breast cancer. Timely evaluations for adverse reactions, a reduced starting dose, or dose escalation as used in the TRADE study may allow patients to continue therapy longer and therefore maximize efficacy.